PGZ Stock Chart & Stats
€0.19
€0.00(0.00%)
At close: 4:00 PM EDT
€0.19
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.17 - €0.62
Previous CloseN/A
Volume0.00
Average Volume (3M)34.00
Market Cap
€190.67M
Enterprise Value€1.21K
Total Cash (Recent Filing)€67.20M
Total Debt (Recent Filing)€998.70M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Feb 24, 2027EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding726,178,800
10 Day Avg. Volume100
30 Day Avg. Volume34
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.65
Price to Sales (P/S)0.21
P/FCF Ratio1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.28Price Target Upside45.59% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering6
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€873.66M
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryThe strong FY2026 top-line recovery indicates renewed demand for pathology and diagnostic imaging services. Sustained volume and referral growth could improve operating leverage and restore scale across Healius’s healthcare network.
Persistent Free Cash FlowConsistent positive cash generation despite accounting losses supports liquidity, ongoing investment and debt repayment. This conversion of activity into cash provides resilience while management works to restore sustainable profitability.
Debt ReductionMeaningful deleveraging reduces interest and refinancing pressure, improving financial flexibility over the medium term. Lower debt also allows more operating cash flow to support laboratories, imaging equipment and network productivity.
Bears Say
Four Years Of Net LossesRepeated annual losses show that Healius has not yet translated its diagnostic network and revenue recovery into dependable shareholder profitability. Continued losses could constrain investment capacity and weaken confidence in the business model.
Unstable Operating MarginsVolatile and weak margins indicate limited earnings resilience despite the FY2026 revenue rebound. Cost pressures, service mix and reimbursement economics may prevent incremental revenue from producing durable profit improvement.
Contracted Equity BaseA smaller equity base reduces the balance sheet cushion available to absorb further losses or fund expansion. Deeply negative returns also show that capital has not been employed effectively, limiting financial flexibility.
Healius Limited News
PGZ FAQ
What was Healius Limited’s price range in the past 12 months?
Healius Limited lowest stock price was €0.17 and its highest was €0.61 in the past 12 months.
What is Healius Limited’s market cap?
Healius Limited’s market cap is €190.67M.
When is Healius Limited’s upcoming earnings report date?
Healius Limited’s upcoming earnings report date is Feb 24, 2027 which is in 180 days.
How were Healius Limited’s earnings last quarter?
Healius Limited released its earnings results on Aug 18, 2026. The company reported -€0.002 earnings per share for the quarter, missing the consensus estimate of <€0.001 by -€0.002.
Is Healius Limited overvalued?
According to Wall Street analysts Healius Limited’s price is currently Undervalued.
Does Healius Limited pay dividends?
Healius Limited does not currently pay dividends.
What is Healius Limited’s EPS estimate?
Healius Limited’s EPS estimate is >-0.01.
How many shares outstanding does Healius Limited have?
Healius Limited has 726,178,800 shares outstanding.
What happened to Healius Limited’s price movement after its last earnings report?
Healius Limited reported an EPS of -€0.002 in its last earnings report, missing expectations of <€0.001. Following the earnings report the stock price went down -7.813%.
Which hedge fund is a major shareholder of Healius Limited?
Currently, no hedge funds are holding shares in DE:PGZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Healius Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
€0.28 (45.59% Upside)
€0.28 (45.59% Upside)
Blogger Sentiment
Bullish
DE:PGZ Sentiment 94%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.41%
Trailing 12-Months
Company Description
Healius Limited
Healius Limited is an Australian firm dedicated to delivering specialized diagnostic services to both individual consumers and healthcare practitioners. Its operations are structured into four primary segments: Pathology, Medical Imaging, Day Hospitals, and other miscellaneous services. The company's core offerings include comprehensive diagnostic imaging, private medical laboratory analysis, and various pathology services. Furthermore, under a diverse portfolio of brands such as Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs, alongside Lumus Imaging and Montserrat, Healius also facilitates a wide array of specialized surgical procedures. These encompass cataract removal, colonoscopies, gastroscopies, plastic and cosmetic operations, skin cancer excisions, IVF egg collection, and gynecological surgeries. The company boasts an extensive network across Australia, comprising 2,105 pathology facilities, 11 day hospitals, and 134 imaging centers. Established in 1994, the entity was originally known as Primary Health Care Limited, adopting the Healius Limited name in December 2018. Its corporate headquarters are situated in Sydney, Australia.
PGZ Stock 12 Month Forecast
Average Price Target
€0.28
▲(45.59% Upside)
Technical Analysis
Lumos Diagnostics Holdings Ltd.
―
Sonic Healthcare Limited
―
Integral Diagnostics Ltd.
―
Australian Clinical Labs Ltd
―
Monash IVF Group Ltd
―






